MY170067A - Method for the treatment of hypercholesterolemia - Google Patents
Method for the treatment of hypercholesterolemiaInfo
- Publication number
- MY170067A MY170067A MYPI2014002207A MYPI2014002207A MY170067A MY 170067 A MY170067 A MY 170067A MY PI2014002207 A MYPI2014002207 A MY PI2014002207A MY PI2014002207 A MYPI2014002207 A MY PI2014002207A MY 170067 A MY170067 A MY 170067A
- Authority
- MY
- Malaysia
- Prior art keywords
- reducing
- mammals
- hypercholesterolemia
- concentrations
- density lipoproteins
- Prior art date
Links
- 208000035150 Hypercholesterolemia Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 4
- 241000124008 Mammalia Species 0.000 abstract 3
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract 2
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract 2
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract 2
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- UYEWRTKHKAVRDI-UHFFFAOYSA-N Calebin A Natural products C1=C(O)C(OC)=CC(C=CC(=O)COC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 UYEWRTKHKAVRDI-UHFFFAOYSA-N 0.000 abstract 1
- UYEWRTKHKAVRDI-ASVGJQBISA-N Calebin A Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)COC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 UYEWRTKHKAVRDI-ASVGJQBISA-N 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000007726 management method Methods 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/259,404 US9668999B2 (en) | 2014-04-23 | 2014-04-23 | Method for the treatment of hypercholesterolemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY170067A true MY170067A (en) | 2019-07-03 |
Family
ID=50828681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2014002207A MY170067A (en) | 2014-04-23 | 2014-07-25 | Method for the treatment of hypercholesterolemia |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9668999B2 (enExample) |
| EP (1) | EP2937084B1 (enExample) |
| JP (1) | JP6263707B2 (enExample) |
| KR (1) | KR101647549B1 (enExample) |
| AU (1) | AU2014202312B2 (enExample) |
| CA (2) | CA2850999C (enExample) |
| EA (1) | EA027148B1 (enExample) |
| MY (1) | MY170067A (enExample) |
| PH (1) | PH12014000244A1 (enExample) |
| PL (1) | PL2937084T3 (enExample) |
| TW (1) | TWI622394B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201503805XA (en) * | 2015-04-19 | 2016-11-29 | Sabinsa Corp | Calebin A For Hepatic Steatosis |
| US9539232B1 (en) * | 2016-08-04 | 2017-01-10 | Muhammed Majeed | Calebin A for osteoporosis |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1060352C (zh) * | 1996-02-08 | 2001-01-10 | 袁克兴 | 降脂药及其制备方法 |
| US6811786B1 (en) * | 1999-04-01 | 2004-11-02 | Ganeden Biotech, Inc. | Methods for reducing cholesterol using Bacillus coagulans spores, systems and compositions |
| WO2001030335A2 (en) * | 1999-10-22 | 2001-05-03 | The Board Of Trustees Of The University Of Illinois | Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease |
| US20020012733A1 (en) | 2000-04-12 | 2002-01-31 | The Procter & Gamble Company | Compositions for reducing hypercholesterolemia and controlling of postprandial blood glucose and insulin levels |
| JP2005232059A (ja) * | 2004-02-18 | 2005-09-02 | Iichiro Shimomura | 低アディポネクチン血症予防・治療剤 |
| JP4834824B2 (ja) * | 2004-07-08 | 2011-12-14 | 独立行政法人産業技術総合研究所 | アディポネクチン産生増強剤 |
| JP2010018522A (ja) * | 2007-03-23 | 2010-01-28 | Hiroshima Univ | アディポネクチン産生促進剤 |
| JP5294165B2 (ja) * | 2007-03-23 | 2013-09-18 | ナガセケムテックス株式会社 | アディポネクチン上昇剤 |
| CN101301455A (zh) * | 2008-07-01 | 2008-11-12 | 崔井朝 | 一种治疗高脂血症的中药复方姜黄固体分散体 |
| JP2011063543A (ja) * | 2009-09-17 | 2011-03-31 | Kao Corp | アディポネクチン増加剤 |
| KR101702702B1 (ko) * | 2011-01-10 | 2017-02-03 | 무하메드 마제에드 | 칼레빈 ａ의 항-비만 가능성 |
-
2014
- 2014-04-23 US US14/259,404 patent/US9668999B2/en active Active
- 2014-04-29 AU AU2014202312A patent/AU2014202312B2/en not_active Ceased
- 2014-05-01 CA CA2850999A patent/CA2850999C/en active Active
- 2014-05-01 CA CA2963383A patent/CA2963383C/en active Active
- 2014-05-02 JP JP2014095457A patent/JP6263707B2/ja not_active Expired - Fee Related
- 2014-05-08 PL PL14167512T patent/PL2937084T3/pl unknown
- 2014-05-08 EP EP14167512.4A patent/EP2937084B1/en active Active
- 2014-06-10 KR KR1020140070179A patent/KR101647549B1/ko not_active Expired - Fee Related
- 2014-07-25 MY MYPI2014002207A patent/MY170067A/en unknown
- 2014-08-26 PH PH12014000244A patent/PH12014000244A1/en unknown
- 2014-09-03 TW TW103130375A patent/TWI622394B/zh not_active IP Right Cessation
- 2014-09-17 EA EA201491545A patent/EA027148B1/ru unknown
-
2015
- 2015-03-03 US US14/637,081 patent/US9610273B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150122552A (ko) | 2015-11-02 |
| US9610273B2 (en) | 2017-04-04 |
| CA2963383C (en) | 2018-12-04 |
| KR101647549B1 (ko) | 2016-08-10 |
| NZ624269A (en) | 2014-12-24 |
| TW201540295A (zh) | 2015-11-01 |
| CA2850999A1 (en) | 2015-10-23 |
| PH12014000244B1 (en) | 2016-08-08 |
| EA201491545A1 (ru) | 2015-10-30 |
| EP2937084A1 (en) | 2015-10-28 |
| JP2015209424A (ja) | 2015-11-24 |
| US9668999B2 (en) | 2017-06-06 |
| TWI622394B (zh) | 2018-05-01 |
| JP6263707B2 (ja) | 2018-01-24 |
| CA2963383A1 (en) | 2015-10-23 |
| AU2014202312B2 (en) | 2018-02-22 |
| CA2850999C (en) | 2018-04-03 |
| EA027148B1 (ru) | 2017-06-30 |
| PH12014000244A1 (en) | 2016-08-08 |
| AU2014202312A1 (en) | 2015-11-12 |
| US20150306060A1 (en) | 2015-10-29 |
| PL2937084T3 (pl) | 2017-05-31 |
| US20150306059A1 (en) | 2015-10-29 |
| EP2937084B1 (en) | 2016-11-30 |
| HK1210590A1 (en) | 2016-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY199017A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy | |
| MX2020004023A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| MX2021000898A (es) | Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| BR112014012607A2 (pt) | métodos de tratamento usando um inibidor de interferon gama | |
| WO2014004993A3 (en) | Methods of reducing ldl-p | |
| EA201990684A1 (ru) | Способы применения оксигенированных холестеролсульфатов (ocs) | |
| EP4403213A3 (en) | Methods for reducing cardiovascular risk | |
| AR094740A1 (es) | Antiadhesión de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3 | |
| MY178654A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy | |
| MX2016005532A (es) | Metodos para usar oxido nitrico en un estado de plasma para tratar condiciones medicas y enfermedades. | |
| MX2016010504A (es) | Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas. | |
| EA201590655A8 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| BR112015024621A2 (pt) | c. novyi para o tratamento de tumores sólidos em seres humanos | |
| CO2018007165A2 (es) | Terapia génica para tratar hipercolesterolemia familiar | |
| BR112013028420A2 (pt) | tratamento de mieloma múltiplo | |
| BR112014009785A8 (pt) | método para tratar ou reduzir efp | |
| EA201590883A1 (ru) | Лечение помалидомидом рака у субъекта с почечной недостаточностью | |
| EA201690284A1 (ru) | Композиции и терапевтические способы для ускоренного регресса бляшки | |
| BR112015001521A2 (pt) | previsão de resposta ao tratamento para inibidor jak/stat | |
| EA201790563A1 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
| MX2015015036A (es) | Metodos para mejorar los perfiles de lipidos utilizando atrasentan. | |
| SG10201807318RA (en) | Methods for treating chronic obstructive pulmonary disease using benralizumab | |
| BR112016029012A2 (pt) | método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina | |
| PH12014500094A1 (en) | Combination als therapy |